FMC (FMC) AGM 2026 summary

Opening remarks and agenda

• The meeting was called to order by the Chairman, CEO, and President, with all board members introduced and rules of order outlined for participants.

• Remembrance was given for a recently deceased director and recognition for three retiring board members for their long service and contributions.

Financial performance review

• Full year revenue was $3.47 billion, down 18% from 2024; adjusted EBITDA was $843 million, down 7%; adjusted EPS was $2.96, down 15%.

• Maintained a strong adjusted EBITDA margin of 22% through cost discipline.

• Divestment of the commercial business in India was announced to address market challenges and high working capital needs.

Strategic initiatives and plans

• Sale of the India commercial business is expected to close this year, with continued participation via supply agreements for patented products.

• Project Foundation was launched to optimize manufacturing and reduce structural costs, including relocating production of two active ingredients.

• Innovation pipeline delivered $200 million in sales from three new active ingredients, up 54% from 2024.

• Board authorized a process to explore strategic alternatives, including a potential sale of the company, while executing the 2026 operational plan.